Your browser doesn't support javascript.
loading
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre, C M; Licht, C; Muus, P; Greenbaum, L A; Babu, S; Bedrosian, C; Bingham, C; Cohen, D J; Delmas, Y; Douglas, K; Eitner, F; Feldkamp, T; Fouque, D; Furman, R R; Gaber, O; Herthelius, M; Hourmant, M; Karpman, D; Lebranchu, Y; Mariat, C; Menne, J; Moulin, B; Nürnberger, J; Ogawa, M; Remuzzi, G; Richard, T; Sberro-Soussan, R; Severino, B; Sheerin, N S; Trivelli, A; Zimmerhackl, L B; Goodship, T; Loirat, C.
Affiliation
  • Legendre CM; Université Paris Descartes and Assistance Publique­Hôpitaux de Paris, Hôpital Necker, INSERM Unité 845, Paris, France. christophe.legendre@nck.aphp.fr.
N Engl J Med ; 368(23): 2169-81, 2013 Jun 06.
Article in En | MEDLINE | ID: mdl-23738544
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement C5 / Thrombotic Microangiopathies / Antibodies, Monoclonal, Humanized / Hemolytic-Uremic Syndrome Type of study: Etiology_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2013 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement C5 / Thrombotic Microangiopathies / Antibodies, Monoclonal, Humanized / Hemolytic-Uremic Syndrome Type of study: Etiology_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2013 Document type: Article